Response to Immunotherapy in MMR-deficient Localized Colon Cancer
Status:
Not yet recruiting
Trial end date:
2028-07-01
Target enrollment:
Participant gender:
Summary
The aim of this study is to evaluate the safety and efficacy of neoadjuvant treatment with
pembrolizumab before colonic resection in patients with early-stage (I-III) deficient
mismatch repair (dMMR) colon cancer (CC).
Phase:
Phase 2
Details
Lead Sponsor:
Camilla Qvortrup
Collaborators:
Aalborg University Hospital Aarhus University Hospital Bispebjerg Hospital Herlev and Gentofte Hospital Horsens Hospital Odense University Hospital Randers Regional Hospital Vejle Hospital Zealand University Hospital